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Cross-species malaria immunity induced
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Stephen L. Hoffman,5 Moses Lee,6 and Virginia McPhun1
1Institute
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3Queensland

Vaccine development for the blood stages of malaria has focused on the induction of antibodies to parasite
surface antigens, most of which are highly polymorphic. An alternate strategy has evolved from observations that low-density infections can induce antibody-independent immunity to different strains. To test
this strategy, we treated parasitized red blood cells from the rodent parasite Plasmodium chabaudi with secocyclopropyl pyrrolo indole analogs. These drugs irreversibly alkylate parasite DNA, blocking their ability
to replicate. After administration in mice, DNA from the vaccine could be detected in the blood for over 110
days and a single vaccination induced profound immunity to different malaria parasite species. Immunity
was mediated by CD4+ T cells and was dependent on the red blood cell membrane remaining intact. The
human parasite, Plasmodium falciparum, could also be attenuated by treatment with seco-cyclopropyl pyrrolo indole analogs. These data demonstrate that vaccination with chemically attenuated parasites induces
protective immunity and provide a compelling rationale for testing a blood-stage parasite-based vaccine
targeting human Plasmodium species.
Introduction
The development of a vaccine for malaria is seen as the best hope
to significantly reduce the burden of disease (1–3). Vaccine development for the blood stages has focused on individual antigens
expressed on the parasite or infected rbc surface primarily because
antibodies induced by recombinant forms of these antigens can
induce immunity in model systems. However, despite initial
promise with one vaccine candidate, MSP2 (4), none of these subunit vaccine approaches have translated to success in late-stage
clinical trials (e.g., refs. 5, 6), although there has been no followup with MSP2. Evidence suggests that this is in large part due to
the extensive polymorphisms that occur in these proteins (7) and
to the fact that very high titer antibody responses are required for
efficacy (8, 9). Virtually all vaccine trials have focused on Plasmodium falciparum, even though the other species that infect humans,
particularly Plasmodium vivax, also cause significant morbidity
and mortality (10).
Over the last 10 years, evidence has accumulated that lowdensity blood-stage infections that are curtailed by antimalaria
drug therapy (and in which parasitemia is below the threshold
detectable by microscopy) can induce immunity in both human
and rodent systems (11, 12). Although further work is required
to validate results from human volunteers (11), due to concerns
with the half-life of the drug previously used (13), in rodent
models, immunity was shown to be species- and strain-transcendent (12). Unlike immunization with a subunit vaccine, exposure to whole organisms has the advantage of inducing immune
responses to multiple plasmodial antigens, many of which are
likely to be highly conserved between strains or species (14). An
additional difference between subunit vaccination and immuniConflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J Clin Invest. 2013;123(8):3353–3362. doi:10.1172/JCI66634.

ty induced by exposure to a low-density infection is that immunity in the latter is antibody independent and T cell dependent
(11, 12). While high parasite load is a critical determinant driving T cells to undergo apoptosis during normal infection, exposure to parasites at low density leads to T cell activation (11, 15).
In humans, this immunity involves both CD4+ and CD8+ T cells
as well as induction of nitric oxide synthase and the absence of
any detectable antibody response to defined merozoite surface
proteins or to antigens expressed on the surface of infected rbcs
(11). Subsequent experiments demonstrated that low doses of
Plasmodium chabaudi parasites killed by freeze/thawing, when
combined with the Th1 T cell–activating adjuvant CpG, could
also induce antibody-independent immunity to various strains
and species of Plasmodium (16). The adjuvant was critical for vaccine efficacy. Others have recently shown protection following
immunization with low doses of nucleoside transporter-1 genetically attenuated Plasmodium yoelii blood-stage parasites which
induced a limited microscopic infection during the immunization period (17). However, these approaches are marred by difficulties in identifying a suitable human-compatible adjuvant
capable of replicating the immunity induced in mice by killed
parasites (16) and concerns that a parasite genetically modified
in only one or a few regions of its genome might revert to a virulent phenotype (18).
Given that exposure to live parasites at low density (without
an adjuvant) induces immunity, we asked whether low doses of
live blood-stage parasites attenuated by a chemical treatment
that irreversibly alkylates the parasite’s DNA in multiple sites
(19) could also induce immunity. While chemically attenuated
intact sporozoite stage parasites (the stage inoculated by mosquitoes and which travel to the liver to continue their life cycle) can
induce immunity (20, 21), DNA chemical attenuation of blood
stages has never been pursued as a vaccine strategy.
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Results
Attenuated parasites persist and induce cross-species protective immunity.
We initially treated P. chabaudi parasitized rbcs (prbcs), 98% of
which were at the early “ring” stage, with the seco-cyclopropyl pyrrolo indole analogs AS-I-145 (centanamycin), TH-III-149 (tafuramycin A), and AS-VIII-104 for 40 minutes in vitro. The prbcs were
washed 3 times to remove excess drug, and then 106 treated cells
were administered i.v. to immunodeficient SCID mice to ascertain attenuation. Mice were followed for 6 weeks for the appearance of any “breakthrough,” parasites but none were detected
microscopically. We also analyzed the blood from SCID and normal mice receiving centanamycin-attenuated and WT parasites
using a quantitative PCR (qPCR) assay based on the 18S rRNA
gene of Plasmodium (Figure 1A). Based on this assay, we showed
that most attenuated (and WT) parasites were removed from the
blood within 5 minutes of administration. For up to 24 hours after
administration of either attenuated or WT parasites to normal
mice, DNA levels were similar. After that time, DNA levels then
increased rapidly in mice given WT parasites as the infection progressed. However, DNA from the attenuated parasites persisted at
low but fluctuating levels in the blood of SCID and normal mice
for over 110 days. In a repeat experiment, we used 15 mice and
divided them into 3 groups of 5 so that more blood could be taken
from each mouse at each time point up to day 51 (collecting 50 μl
instead of 20 μl of blood to increase the sensitivity of the assay)
(Supplemental Figure 1; supplemental material available online
with this article; doi:10.1172/JCI66634DS1). As reported in Figure 1, DNA was detectable at low but fluctuating levels and all
mice survived. It was not clear whether these low but fluctuating
levels of DNA represented viable parasites or simply DNA from
nonviable parasites. To explore further whether or not viable parasites were present in the blood of vaccinated mice, xenodiagnosis
was undertaken. Blood from vaccinated mice was transferred to
naive BALB/c mice (100 μl per mouse). None of the 20 mice that
received the blood developed a patent parasitemia, suggesting that
the parasites were not viable in the donors at the time of transfer.
Parasites attenuated with each of the seco-cyclopropyl pyrrolo
indole analogs were next administered i.v. to immunocompetent
A/J mice. The infection is lethal in this mouse strain. Five weeks
after a single immunizing dose of 106 attenuated P. chabaudi parasites, the mice were challenged with 105 homologous WT parasites and were strongly protected (Figure 1B). Clinical scores were
recorded for all mice and none of the vaccinated mice demonstrated any adverse clinical effects as a result of the vaccination or the
challenge infection. Although P. chabaudi is not lethal in C57BL/6
mice, we observed that the centanamycin-attenuated vaccine could
also induce strong antiparasitic immunity in this mouse strain
(Figure 1C). In various experiments, control A/J mice immunized
with uninfected rbcs treated with centanamycin, injected with
saline, or receiving no treatment all developed a rapid infection
following challenge and succumbed (data not shown). In other
experiments, we observed protection following immunization
with 104 attenuated parasites (data not shown) and also observed
that 3 immunizations did not lead to enhanced protection over a
single immunization (Supplemental Figure 2).
We next asked whether immunity was long lived and observed
that A/J mice challenged 6 months after a single immunization with
attenuated prbcs from a different parasite, P. yoelii, were strongly
protected against homologous challenge (Supplemental Figure 3).
To ask whether immunity resulted in cross-species protection, we
3354

vaccinated mice with centanamycin-attenuated parasites prepared
from P. chabaudi strain AS, challenged them with the heterologous
species, Plasmodium vinckei and P. yoelii, and also observed strong protection (Figure 1D). Mice were also vaccinated with centanamycinattenuated parasites prepared from P. chabaudi strain AS and challenged initially with the homologous strain, then 3 months later
with the heterologous strain, P. chabaudi AJ. We observed strong
protection against the original homologous parasite and the subsequent heterologous challenge (Supplemental Figure 4).
Attenuated parasites induce a cellular immune response. To examine
the nature of immunity, we initially determined the fate of attenuated P. chabaudi prbcs in vivo. We confirmed the rapid diminution
of attenuated parasite numbers in the blood shown by qPCR (Figure 1) using an assay in which we tracked parasitized and normal
rbcs by labeling the rbc membranes with DiI (22) and parasite
DNA with Hoechst (HO) stain 34580. We demonstrated that
chemically attenuated prbcs were removed from the circulation
far more rapidly than normal rbcs (nrbcs) (Figure 2A). Attenuated
parasites accumulated in the spleen and liver as determined by
flow cytometry (Figure 2B) and were shown to be inside F4/80+
cells (macrophages) and CD11c+ dendritic cells (Figure 2, C and
D). Confocal imaging confirmed that HO+DiI+ cells could be seen
within F4/80+ cells in the spleen (Supplemental Figure 5B). These
data suggested that attenuated parasites might rapidly activate the
immune system.
To measure early activation of the immune system, we monitored CD11a and CD49d expression on T cells (23) and observed
that within 5 days of administration of centanamycin-attenuated P. chabaudi prbcs, 1.2% of peripheral blood CD4 + T cells
showed significant activation above the level of activation in
mice that received a saline injection (P < 0.0001) and that the
mean number of activated cells rose to 5% by 21 days (Figure
3A and Supplemental Figure 6). There was less activation of
CD8+ cells. When tested 2 months after vaccination, spleen cells
showed a strong proliferative response to homologous prbcs as
well as to prbcs of the heterologous species P. yoelii, but not to
uninfected rbcs (Figure 3B). Spleen cells from a naive mouse did
not respond to the parasites.
To determine whether the T cells were functional, splenic CD4+
and CD8+ T cells were examined for intracellular IFN-γ 5 days
after vaccination with centanamycin-attenuated parasites, centanamycin-treated nrbcs, or saline. Cells were activated in vitro
for 4 hours with PMA/ionomycin prior to staining (as described
in ref. 23). There were significantly more cytokine-positive cells in
the spleens of vaccinated mice compared with the other groups of
mice (Figure 3C). Furthermore, spleen cells from vaccinated mice
produced larger amounts of IFN-γ and MCP-1 ex vivo in response
to prbcs compared with nrbcs or medium alone (Figure 3D).
To confirm that vaccination induced expansion and activation
of antigen-specific CD4+ T cells, rather than bystander activation,
we transferred congenic (CD45.1) OVA-TCR transgenic OTII cells
into CD45.2 recipients, which we vaccinated with attenuated parasites or OVA peptide/LPS, and observed activation of the OTII cells
following OVA peptide administration, but not following vaccination with attenuated parasites. Conversely, we observed activation
of CD45.2 CD4+ T cells following vaccination with centanamycintreated prbcs, but not following administration of centanamycintreated nrbcs or OVA. These data demonstrate that the vaccine
induced expansion and activation of antigen-specific CD4+ T cells,
without activation of bystander T cells (Figure 3E).
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Figure 1
Immunization with attenuated parasites. (A) Immunodeficient SCID mice (left panel) or immunocompetent A/J mice (right panel) were administered 106 (left panel) or 107 (right panel) P. chabaudi prbcs attenuated with 2 μM centanamycin or 107 WT parasites (right panel). qPCR was
performed to estimate parasite density in the blood at various time points. y axes show the estimated parasite density. (B) To assess immunity,
A/J mice (5 per group) were immunized with a single dose of 106 P. chabaudi prbcs attenuated with centanamycin, TH-III-149, or AS-VIII-104, as
indicated, or left untreated. All were challenged 5 weeks later with 105 P. chabaudi prbcs i.v. (C) To assess immunity in a different mouse strain,
C57BL/6 mice were either immunized with a single dose of 106 P. chabaudi prbcs attenuated with centanamycin or given a saline injection (control) and challenged 9 weeks later with 105 P. chabaudi prbcs i.v. (D) TH-III-149 (for P. vinckei challenge) or centanamycin (for P. yoelii challenge)
were used to attenuate P. chabaudi, and mice were immunized with a single dose of 106 prbcs and challenged 4 weeks later with either 104
P. vinckei or 104 P. yoelii prbcs i.v. Plus signs indicate that mice succumbed to the infection.

To determine whether the vaccine-induced, antigen-specific
CD4+ T cells were protective, immunized mice were given antibodies to clear more than 98% of their CD4+ T cells or more than
89% of CD8 + T cells (Supplemental Figure 7) and then challenged. Control mice that received normal rat immunoglobulin
showed complete protection, but CD4+ T cell–depleted mice all
succumbed, albeit more slowly than naive mice (Supplemental
Figure 8). When CD8+ T cells were depleted from immune mice,
we observed no change in their level of immunity. Thus, CD8 +

T cells alone are not able to provide complete protection, but
they or other cell types may contribute a minor role.
Although CD4+ T cells were critical for protection, we were not
able to transfer protection with purified CD4+ T cells. Thus, 107
CD45.2 splenic CD4+ T cells from C57BL/6 mice immunized 3
times with centanamycin-attenuated P. chabaudi prbcs or equivalent numbers of naive CD45.2 T cells were transferred into CD45.1
congenic naive mice that had been pretreated 3 days earlier with 1
dose of anti-CD4 mAb to deplete most endogenous T cells. CD4+
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Figure 2
Tracking of attenuated parasites stained with DiI and HO. rbcs from a P. chabaudi–infected mouse (parasitemia, 39.8%; Supplemental Figure 5A)
were treated with centanamycin, stained with DiI and HO, and then injected i.v. into naive AJ mice (3 mice, 5 × 107 cells per mouse). rbcs from an
uninfected mouse were stained with DiI alone and injected into other mice (3 mice, 5 × 107 cells per mouse). DiI+HO– cells (nrbcs) or DiI+HO+ cells
(prbcs) in the peripheral blood of recipient mice were analyzed over time by flow cytometry and the percentage of these cells of the total injected
nrbcs or prbcs calculated based on an assumption of the recipient mice each containing a total of 5 × 109 rbcs (A). Spleen and liver cells of recipient mice were prepared by mechanical disruption. rbcs were gated and DiI+HO+ cells identified. The percentages of DiI+HO+ cells of the total rbcs
in the spleen and liver were then calculated (B). Free rbcs were then lysed using NH4Cl-Tris buffer to allow estimation of rbc uptake by white cells.
Percentages of DiI+HO+F4/80+ or DiI+HO+CD11c+ cells in total F4/80+ (C) or CD11c+ cells (D) in the spleen and liver were then calculated. Two
independent experiments were performed (total n = 4–6 mice per time point), and representative graphs are shown. Means ± SEM are shown.

T cell engraftment was successful, as shown by flow cytometry
with between 5% and 12% of peripheral blood T cells being of
donor origin. Mice were challenged 11 days after transfer, but no
protection was observed, despite control animals vaccinated with
centanamycin-treated prbcs being protected.
We next asked whether mice immunized with either 104 or 106
chemically attenuated parasites developed parasite-specific antibodies. Using an ELISA to whole parasite antigens, we observed that
while sera taken from mice that experienced multiple infections
each followed by drug cure contained antibodies, sera from mice
immunized with attenuated parasites did not (Supplemental Figure
9A). In a repeat experiment to confirm protection in the absence of
antibodies, we observed that not only were antibodies not detectable after vaccination, but that following challenge (during which
parasites were not detectable by microscopy in any of the vaccinated
recipients), antibodies were also not detected (Supplemental Figure
9B). In a further experiment to ascertain any role for antibodies, sera
from 10 vaccinated A/J mice and from 10 control mice were transferred into naive recipients (0.5 ml on each of days –1, 0, and 1) that
were challenged on day 0. Mice that received serum from immunized
mice as well as mice that received serum from naive controls all succumbed without any evidence of protection, but the serum donor
mice were protected (Supplemental Figure 9C).
The above data suggest that antigen-presenting cells initiate
an antiparasite CD4+ T cell response following uptake of rbcs
3356

containing attenuated parasites. To further understand the
interactions between attenuated parasites and the cells of the
immune system, we asked whether a preparation of lysed attenuated prbcs would also induce immunity. We immunized mice
with intact or lysed attenuated prbcs and observed that when
the rbc membranes were disrupted, immunity was not induced
(Figure 4A). Therefore, the interaction between the attenuated
parasites and the cells of the immune system requires the rbc
membranes to remain intact. As the spleen is assumed to be a
site where antiparasite immunity is induced (ref. 24 and Figure
2), we examined the importance of the spleen in the induction of
protective immunity. We observed that, while eusplenic control
mice could control parasite burden more effectively than splenectomized control mice, both groups of vaccinated mice could
control parasite burden very effectively and to a similar level at
5 weeks after vaccination (Figure 4B). This demonstrated that
short-term immunity could be induced and mediated in tissues
other than the spleen, with one likely site being the liver (25,
26). However, in an experiment in which mice were challenged
12 weeks after vaccination, we observed that splenectomized
mice were not protected, whereas sham-splenectomized mice
were still protected. This may be due to the presence of spleenresident memory cells mediating protection at later time points
with effector cells, which may have a different tissue localization, mediating protection at earlier time points.
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Figure 3
Immune responses induced by chemically attenuated parasites. (A) C57BL/6 mice (12 per group) were vaccinated with 106 P. chabaudi
prbcs attenuated with centanamycin or injected with saline. Phenotypes of blood CD4+ and CD8+ cells were assessed on days 5 and 21
after vaccination. Values for means of the saline group were subtracted from values for each vaccinated mouse. Each circle represents 1
mouse. Horizontal bars represent means. One sample t test was performed comparing values to the saline mean of zero. (B) Three A/J mice
were immunized with 3 doses of vaccine (each, 106 centanamycin-attenuated P. chabaudi prbcs), and spleen cells from these and a naive
mouse were collected 8 weeks after the last immunization and cultured with indicated antigens; uptake of 3H thymidine was determined after
72 hours as described in Methods. (C) C57BL/6 mice (5 per group) were vaccinated with 106 P. chabaudi prbcs or equivalent nrbcs attenuated with centanamycin and sacrificed on day 5. Spleen cells were stimulated in vitro for 4 hours with PMA and ionomycin in the presence of
BFA and stained for IFN-γ. Percentage that was IFN-γ positive was determined by subtracting isotype control and values from mice injected
with saline for CD4 and CD8 populations. (D) Three A/J mice were immunized with 3 doses of vaccine (each, 10 6 centanamycin-attenuated
P. chabaudi prbcs), and spleen cells from these mice were collected 50 days after the last immunization, cultured with indicated antigens,
and after 72 hours culture, supernatants collected and use for cytokine bead analysis as described in Methods. (E) C57BL/6 mice (CD45.2,
5 per group) were adoptively transferred with OT-II T cells (CD45.1), and 1 group received ovalbumin peptide 323–339 mixed with LPS i.p.
24 hours later, mice were immunized i.v. with 106 P. chabaudi prbcs or equivalent nrbcs attenuated with centanamycin. Mice were bled on
day 6 after immunization and the phenotype of donor and recipient cells determined by flow cytometry. Percentages were calculated by
subtracting values from mice receiving OT-II cells alone.
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Figure 4
Vaccine protection requires an intact rbc membrane. The role of the spleen early (5 weeks) after vaccination. (A) To determine whether the rbc
membrane must remain intact for vaccine efficacy, cohorts of 5 A/J mice were vaccinated with a single dose of 106 P. chabaudi prbcs attenuated
with centanamycin or a vaccine lysed with distilled water, then returned to isotonicity with 2× PBS. Naive mice served as a control. Five weeks
later, mice were challenged with 105 P. chabaudi prbcs i.v. and parasitemia monitored. Plus signs indicate that mice succumbed to the infection. (B) To determine the importance of the spleen to immunity early after vaccination, A/J mice were splenectomized and others had a sham
splenectomy. Four weeks later, half were immunized i.v. with 3 doses of 106 P. chabaudi prbcs attenuated by treatment with centanamycin, each
2 weeks apart. The other half received no treatment. Five weeks after the final dose of vaccine, all mice were challenged with 105 prbcs i.v. and
parasitemia monitored. Plus signs indicate that mice succumbed to the infection.

We next determined whether centanamycin treatment would
result in attenuation of the major human parasite P. falciparum.
It was previously observed that centanamycin could kill P. falciparum in vitro (27). To analyze this further, we measured RNA
transcription and DNA replication after centanamycin treatment
of a synchronized P. falciparum culture containing initially only
rings (Supplemental Figure 10). We showed that, over a 64-hour
time period, very few centanamycin-treated cells progressed
through the cell cycle and that there was near complete arrest
of transcription. This level of attenuation is consistent with our
observations in vivo (above).
Discussion
We show that vaccination with chemically attenuated rodent parasites induces long-lived strain- and species-transcendent immunity
via a mechanism that is CD4+ T cell dependent. At early times after
vaccination (5 weeks), immunity can occur independently of the
spleen, but the spleen appears to play a critical role at later time
points (12 weeks) during the memory phase of the response. Vaccine efficacy requires the presence of intact rbc membranes.
Although T cells are critical for protection, we observed that
splenic CD4+ T cells did not transfer protection. There are 2 likely
explanations. First, the protective T cells of the donor mice were in
the tissues and not resident in the spleen when the spleen cell transfer experiment was performed. As such, protective T cells may not
be transferred in a spleen cell transfer experiment. The fact that the
mature forms of this parasite (schizonts) reside in the tissues and
are not found in peripheral blood lends support to the fact that the
protective T cells may also reside in the deep tissues. While this is a
possibility, we believe that this may be a less likely explanation since
we have shown that T cells from the spleen of vaccinated mice can
respond by proliferation and cytokine production to prbcs. Second,
while T cells are critical for protection (Supplemental Figure 8), other
cell types and/or other changes in the tissues may also be critical. For
example, we know that immunized mice depleted of CD4+ T cells
3358

offer more resistance to infection than naive mice, suggesting that
immune cells other than CD4+ T cells might also contribute to protection. Changes in splenic architecture have also been reported in
mice following P. yoelii and P. chabaudi infection (28, 29), and we cannot rule out the possibility that vaccine-induced immunity occurs
with structural changes in the spleen or other tissues. Furthermore,
it is known that the liver can play an important role in protection
(25, 26). Thus, vaccination with attenuated parasites might also alter
tissue architecture in various tissues to promote antiparasitic immunity that cannot be replicated in a simple cell-transfer experiment in
which normal unexposed mice are the recipients of immune cells.
Further studies are underway to attempt to resolve this issue.
The seco-cyclopropyl pyrrolo indole compounds are known to
bind within the minor groove of parasite DNA in AT rich sequences (19, 27), which are highly abundant in Plasmodium. While we
cannot exclude that these chemicals may have other effects on the
parasite, the data suggest that the primary role of the seco-cyclopropyl pyrrolo indoles is to alkylate the parasite’s AT-rich DNA,
severely compromising its ability to replicate. It is possible that
some parasites may escape complete attenuation and continue a
limited replicative cycle in vivo; the data showing persisting but
fluctuating levels of parasite DNA in vivo support the hypothesis that active parasite replication may be occurring at a very low
level. However, any such replication would appear to be limited, as
transfer of blood from vaccinated mice to naive recipients (xenodiagnosis) failed to establish a patent infection. There are potential concerns regarding a replicating parasite vaccine, including
whether a more virulent phenotype would emerge and whether or
not transmission might occur to another individual. While our
data suggest that these will not be of concern, this nevertheless is
something that will need to be carefully studied in clinical trials.
The results presented here strongly suggest that antigens expressed
during the ring stage are responsible for the induction of protective
immunity. We cannot exclude the possibility that a vaccine based
on other stages (e.g., trophozoites) would also be effective. We chose

The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 8   August 2013

Downloaded on October 24, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/66634

research article
ring-stage parasites for these studies because they are readily harvested at more than 98% purity from the blood of infected mice,
whereas the mature forms are sequestered in deep tissues. Whether
the immune response induced by the ring-stage vaccine responds
to all stages or simply the ring stages is not known. However, it is
known that many antigens are expressed throughout the various rbc
stages (www.PlasmoDB.org and ref. 30). It seems likely that vaccineinduced CD4+ T cells are reactivated by the different blood stages
of Plasmodium at the start of an infection and that they then promote a cell-mediated immune response that prevents further parasite growth. Evidence from other studies (e.g., refs. 1, 2, 31, 32) collectively suggests that these CD4+ T cell–dependent, cell-mediated
mechanisms include macrophage activation, phagocytosis, and the
release of small inflammatory molecules such as nitric oxide.
A critical question for vaccine development is whether the data
observed in a rodent model using a P. chabaudi vaccine will translate to an efficacious and safe multispecies vaccine for humans.
While this question will only be satisfactorily answered following
human clinical trials, the data presented here, and elsewhere (11,
12), suggest that this approach will be successful. We show that
the vaccine is effective in different strains of mice, that immunity
is cross-species protective, and that attenuated parasites prepared
using a different rodent malaria species, P. yoelii, are also highly
effective. This is the first time, to our knowledge, that any vaccine preparation has shown protection against the highly virulent
P. vinckei (24). We previously demonstrated that deliberate infection of human volunteers with a subpatent P. falciparum infection
(in which the volunteers are drug treated before the microscopic
appearance of parasites and clinical symptoms) induced profound
T cell immunity to the parasite (11). Here, we extend this observation markedly by attenuating the parasites prior to administration
and thus converting the original observation into a vaccine strategy. Collectively, these data are consistent with the hypothesis that
the target antigens for T cells in Plasmodium are highly conserved
across species (14, 16), and because of this, a human parasite vaccine is likely to be effective.
Although a whole parasite vaccine without any human rbc material may be preferable, we show that the intact rbc membrane is
essential for efficacy. Our data suggest that the role of the rbc
membrane is to target the parasite to the antigen-presenting cells,
as has been shown for P. falciparum (33), thereby initiating the antiparasite immune response. The issue of safety in the preparation
of a human vaccine using human rbcs will be addressed in part
by preparing a P. falciparum vaccine in “universal donor” (transfusion-grade blood group O negative) rbcs. This topic has been
discussed (34–37) looking at the recent inoculations of healthy
volunteers with infected rbcs to study immunity and the inoculations of syphilis patients who received malaria therapy in the early
20th century and of volunteers in the latter half of the century who
received deliberate infections to test schizonticides. No adverse
side effects were reported in these studies. Today, stringent quality
assurance makes blood transfusions extremely safe.
Another question relevant to vaccine development is whether
sufficient vaccine can be prepared at scale in vitro. While the dose
of attenuated parasites required to induce immunity in humans
is not known, we are encouraged by the ability of extremely low
parasite densities to activate human T cells (11), which suggests
that very low doses of attenuated parasites may suffice. In those
studies, volunteers received approximately 30 infected rbcs and the
infection was curtailed after one week.

While whole parasite vaccines were not considered a viable and
effective option for malaria until 10 years ago (38), there are now
concerted efforts to develop a whole parasite sporozoite vaccine using either irradiated parasites (39), genetically attenuated
organisms (40), or via sporozoite exposure and drug treatment
(41), with all these approaches entering clinical trials. This has
been driven in large part by the limited efficacy of the leading
subunit sporozoite vaccine, RTS,S (42). Despite a multitude of
blood-stage subunit vaccine candidates, none have progressed
to late-stage trials, underscoring the importance of considering
whole parasite vaccines as alternate strategies for the blood stages
as well. Thus, we present data that we believe for the first time
show that a chemically attenuated blood-stage malaria vaccine is
highly efficacious and exerts its effect via a different mechanism
from that of subunit vaccine candidates. This makes it worthy of
serious consideration as a new approach to developing a malaria
vaccine. Furthermore, the strategy of chemical attenuation and
vaccine development could prove very useful for other organisms,
many of which are known to be susceptible to attenuation by secocyclopropyl pyrrolo indoles (19).
Methods
Mice. Four- to six-week-old female A/J mice (H-2a), BALB/c congenic SCID
(H-2d) and C57BL/6 (H-2b), and B6.SJL-PtprcaPep3b/BoyJArc (Ptprca), were
purchased from the Animal Resource Centre (Willeton, Western Australia).
Animals were maintained in a pathogen-free environment at the Griffith
University Animal Facility.
Parasites. Cloned lines of P. chabaudi isolates AS and AJ, P. yoelii, and
P. vinckei were obtained from The Queensland Institute of Medical
Research from stock originally provided by Richard Carter (University
of Edinburgh, United Kingdom). Stabilates were maintained by i.p. passage of 105 prbcs into naive recipients. PCR amplification of the MSP1
genes was used to confirm parasite identity. Challenge infections were
performed by i.v. injection of 105 prbcs. P. falciparum NF54 strain was
obtained from Sanaria Inc. Parasitemia was monitored from thin blood
smears stained with Giemsa or Diff-Quick (Bacto).
Complete medium for lymphocyte culture. RPMI 1640 (Gibco; Invitrogen)
was supplemented with 10% heat inactivated FBS, penicillin (2 mM),
streptomycin (1,000 U/ml), and 2-mercaptoethanol (0.05 mM) (Gibco;
Invitrogen) to make complete medium.
PCR. For sample preparation and DNA extraction, 10, 20, or 50 μl of
infected blood was collected at different time points in 200 μl of 0.9%
saline. Blood samples were centrifuged at 11,000 g for 5 minutes to pellet
the erythrocytes, and the supernatant was removed. Samples were frozen
at –80°C prior to DNA extraction. Genomic DNA (gDNA) was extracted
using a High Pure PCR Template Preparation Kit (Roche) following the
manufacturer’s instructions. gDNA was eluted in 30 μl elution buffer.
DNA standards were prepared from a whole blood sample from an outbred Quackenbush mouse infected with P. chabaudi AS. Infected blood was
collected through cardiac puncture. 98% of prbcs were at the ring stage.
The parasite density was measured by microscopy, diluted to a concentration of 9.5 × 108 prbcs/ml, aliquoted, and stored at –80°C. gDNA was
extracted fresh for each PCR run from 10 μl of whole blood and serially
diluted to 9.5 prbcs/ml. The data from all curves were analyzed using BioRad CFX manager 2.1 software. The log10 of each known concentration in
the dilution series was plotted against the quantification cycle (Cq values)
in a linear regression model.
qPCR was performed using a Bio-Rad CFX96 Real-Time PCR System. A
68-bp region of the 18S ribosomal RNA (18S rRNA) gene of P. chabaudi AS
(GenBank DQ241815.1) that does not contain any putative centanamy-
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cin-binding sites (AAA[A/T]) was selected as the amplification target. PCR
primers and a TaqMan MGB probe were designed as follows: 18SNCBforward: 5′-ACTTCCATTAATCAAGAACGAAAGTT-3′, 18SNCB-reverse:
5′-TGGTTAAGATTACGATCGGTATCTGA-3′ and 18SNCB-probe: FAM
5′-AAGGGAGTGAAGACGA-3′ MGBNFQ (Applied Biosystems). The PCR
mix consisted of 10 μl SsoFast Probes Supermix (Bio-Rad), 0.2 μM of each
primer, and TaqMan MGB probe and 5 μl of template DNA in a 20 μl
final reaction mix under the following conditions: 2 minutes incubation
at 95°C, followed by 45 cycles of 95°C for 15 seconds and 60°C for 45
seconds. The standards and samples were run in triplicate.
rbc lysis. For analysis of the need for rbc membranes to remain intact for
immunogenicity, the packed rbc volume was measured and 4 times the
volume of sterile distilled water was added to the packed cells. The cells
were resuspended for 2 minutes; then double-strength PBS was added to
restore tonicity. Sample was reconstituted to 5 × 106 equivalent prbcs/ml.
Attenuation and immunization. Infected blood was collected by cardiac
puncture when parasitemia was between 30%–40% and 100 μl diluted to 10
ml in warm serum-free RPMI. AS-I-145 (Centanamycin) (43), TH-III-149
(tafuramycin A) (44), and ASVIII-104 (45) have been previously described.
These were dissolved in DMSO at 10,000× the desired attenuating concentration. Stock solutions of PET (polyethylene glycol 400, absolute ethanol,
and Tween 80 in 6:3:1 portions) and 5% glucose were made and mixed 1:2.
The DMSO solution was then added at 10% volume to the PET/glucose
mix. Attenuating agents were diluted to a 20-μM final concentration in
RPMI and then infected blood added in RPMI to give a final concentration
of 2 μM. The mixture was then incubated at 37°C in a 5% CO2 incubator for 40 minutes. The cells were washed 3 times and counted, and the
immunizing dose was calculated. Mice were immunized i.v. Control mice
received treated nrbcs, saline, or no treatment, as described.
Analysis of P. falciparum attenuation. P. falciparum NF54 parasites were cultivated at 37°C with 5% carbon dioxide/5% oxygen in air using O+ human
erythrocytes (Australian Red Cross Blood Service) in RPMI 1640 containing 25 mM HEPES, 10% O+ human serum (Australian Red Cross Blood Service), l-glutamine, and 25 mg/ml gentamycin (complete culture medium).
Parasites were synchronized with sorbitol treatment and ring-stage parasites prepared (1.8 to 2.0% parasitemia). Parasites were treated with 2 μM
centanamycin at 37°C for 40 minutes and then washed with serum free
RPMI 1640 medium. WT or centanamycin-treated P. falciparum parasites
were grown in complete medium for 64 hours and parasites collected every
16 hours. The culture medium was replaced every 24 hours.
For RNA and DNA staining (46), rbcs were pelleted and resuspended in
400 μl of Retic-COUNT Reagent (thiazole orange [TO]; BD), and then HO
34580 added at a 4-mM final concentration. A total of 100,000 cells were
collected by the LSRFortessa flow cytometer, and data were analyzed by
FACSDiva software. HO and TO signals were detected by 450/50 (excited
by 405 nm) and 530/30 (excited by 488 nm) filters, respectively.
Immunodepletion. Anti-CD4 antibodies were generated from the culture
supernatant of rat anti-mouse CD4, clone GK1.5 (ATTC). Rat anti-mouse
CD8β was generated from clone 53.5.8 (ATCC). Both were purified over a
protein G–sepharose column (Thermo Scientific). 500 μg of anti-CD4 was
administered on days –4, –3, –2, –1, 0, and +1 relative to challenge day. 500 μg
of rat anti-CD8β was administered i.p. on days –4, –3, –2, –1, 0, +1, +3, and +5
relative to the day of challenge. 500 μg of rat IgG (Sigma-Aldrich) was used as
a control antibody. CD4 depletion was shown to be 99% effective, and CD8
depletion was shown to be 98% complete using flow cytometry.
Lymphocyte proliferation assays. Mouse spleens were processed to obtain a
single-cell suspension, diluted to 5 × 106 cells/ml in RPMI 1640 complete
medium, and aliquoted into 96-well plates at 5 × 105 cells/well. Triplicate
wells were cultured with fresh prbcs or nrbcs at 5 × 105/well. Cells were
pulsed with 0.25 μCi of 3[H]-Thymidine (PerkinElmer)/well during the last
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18 hours of a 72-hour culture and harvested onto fiberglass mats; 3H incorporation was measured on a PerkinElmer MicroBeta2 β counter.
Analysis of circulating T cells. Approximately 50 μl of blood was obtained
from the tail of each mouse. rbcs were lysed with ACK and Fc-receptors
blocked with 100 μg/ml heat-inactivated rat IgG for 10 minutes on ice.
Samples were stained for 20 minutes on ice with a biotinylated antiCD49d, followed by washing and staining with anti-CD4 V500 (clone RM
4-5), anti-CD8 PerCP-Cy5.5 (clone 53-6.7), anti-CD11a FITC (clone 2D7),
and streptavidin-APC (all from BD). Samples were fixed with 4% formaldehyde and run on a BD LSRFortessa. Data were analyzed with FlowJo;
saline means were calculated and subtracted from samples using Excel and
graphed using Prism 5 for Mac OS X. One-sample t tests (2 tailed) were
performed with Graph Pad QuickCalcs software (http://www.graphpad.
com/quickcalcs/).
Adoptive transfer. Spleens from 2 female B6.OT-II.Ptprca (CD45.1) mice
were placed into a 100-mm dish containing medium and a 70-μm nylon
cell strainer. The plastic end of a 5-ml syringe was used to gently mash
the spleens, and the cell suspension was strained through the same 70-μm
strainer. The petri dish was rinsed with additional medium. The cell suspension was centrifuged at 300 g for 5 minutes and supernatant aspirated.
rbcs were lysed using 1× Vitalyse buffer for 5 minutes at room temperate
and quenched with excess medium. Cells were centrifuged as above and
isolated using the CD4+ T cell Isolation Kit II (Miltenyi Biotec) according to the manufacturer’s recommendations. Cells were resuspended in
0.9% saline and injected i.v. with either 500,000 or 100,000 cells (for I-A b
restricted chicken ovalbumin peptide 323–339, sequence ISQAVHAAHAEINEAGR, +LPS group) per mouse. The ovalbumin peptide group
received 10 μg of LPS mixed with 30 μg of peptide administered i.p. After
24 hours, mice received either nothing, 1 × 106 P. chabaudi AS centanamycin attenuated prbcs, or equivalent numbers of centanamycin-attenuated
naive rbcs administered i.v. Mice were tail bled approximately 50 μl on day
6 after immunization (day 7 after adoptive transfer) and the phenotype
of donor (OT-II, CD45.1+) and host (B6, CD45.2+) were assessed via flow
cytometry. Cells were stained with antibodies against CD3, CD4, CD11a,
CD49d, CD45.1, and CD45.2. The phenotype and purity of the adoptively
transferred cells was also assessed and was found to be 80% CD3+CD4+.
T cell transfer for protection. Ten female Ptprca (CD45.1) mice received a
single dose of 100 μg anti-CD4 monoclonal antibody (clone YTS191.1)
i.v. on day 3 prior to adoptive transfer. Spleens from 5 female C57BL/6
mice 3 days after the third immunization with 106 P. chabaudi AS centanamycin–attenuated prbcs or from naive C57BL/6 mice were processed (as
described above for adoptive transfer) and CD4+ T cells isolated. 107 CD4+
T cells were injected i.v. per CD4-depleted Ptprca mouse. Mice were challenged with 105 P. chabaudi AS prbcs i.v. on day 11 after transfer. Additionally, naive Ptprca mice and thrice immunized C57BL/6 that received either
centamycin-attenuated nrbcs or P. chabaudi AS prbcs were all also challenged on the same day. Parasitemias and clinical scores were monitored.
On day 7 after challenge, approximately 50 μl of blood was collected via
tail from Ptprca mice that received no cells or CD4+ T cells from naive or
immunized mice and evaluated for phenotype of host and recipient cells.
Percent chimerism was calculated as the percentage of leukocytes that
were CD3+CD4+CD45.2+CD45.1–.
Intracellular staining for IFN-γ. Spleens were individually processed in a
well of a 6-well plate containing 5 ml medium and a 70-μm nylon cell
strainer. The rubber end of a 10-ml syringe was used to gently mash
each spleen, and the cell suspensions were strained through their respective 70-μm strainers. Each well was rinsed with additional medium. The
cell suspension was spun at 400 g for 5 minutes and supernatant aspirated. rbcs were lysed using 1× Vitalyse buffer for 5 minutes at room
temperate and quenched with excess medium. Cells were spun as above
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and resuspended to 10 7 cells per ml and 100 μl (10 6) cells added per
well into a round-bottomed 96-well plate. All wells received brefeldin
A (BFA) at a final concentration of 10 μg/ml or with the addition of 5
× 106 P. chabaudi AS prbcs or equivalent nrbcs or with final concentrations of 0.1 μg/ml PMA and 0.1 μM ionomcyin (all from Sigma-Aldrich).
Cells were cultured for 4 hours at 37°C and centrifuged at 400 g for
5 minutes; supernatants were removed by flicking. Cells were washed
with PBS and resuspended in PBS containing yellow live/dead fixable
stain (Invitrogen) (1:100) and incubated for 30 minutes on ice protected
from light. Cells were washed with PBS and Fc receptors blocked by
incubating for 10 minutes on ice with 2.4 G2 antibody supernatant.
Cells were centrifuged and resuspended in 50 μl of surface antibodies
(CD4,CD8,CD11a,CD49d) in PBS and incubated on ice for 20 minutes.
Cells were washed three times and resuspended in BD Fix/Perm buffer
according to the manufacturer’s recommendations. Cells were subsequently stained with anti–IFN-γ or rat IgG1 isotype control antibodies
in fix/perm wash buffer for 20 minutes on ice. After washing, cells were
resuspended in 1% paraformaldehyde in PBS and kept at 4°C protected
from light until run on a BD LSRFortessa cytometer.
Cytokine bead array. Three A/J mice were immunized with 3 doses of vaccine (each consisting of 106 centanamycin-attenuated P. chabaudi prbcs),
and spleen cells from these mice were collected 50 days after the last
immunization, cultured with indicated antigens (as described above for
proliferation assay); after 72 hours, culture supernatants were collected.
Supernatants from duplicate wells were used for the Mouse Inflammation
Kit Cytometric Bead Array (BD) according to the manufacturer’s recommendations, except that volumes of samples and standards were scaled
down to 10 μl and 2 μl of each capture bead was used. Samples were run on
a BD LSRFortessa cytometer and data analyzed with FCAP array (v1.01 for
Windows) software (BD).
ELISA. To prepare crude parasite antigen, blood from mice infected with
P. chabaudi AS at peak parasitemia was collected, washed in PBS, and incubated with 0.01% (wt/vol) saponin (Sigma-Aldrich) at 37°C for 20 minutes.
The pellet was washed in PBS, resuspended in PBS, and sonicated. 96-well
MaxiSorp Nunc immunoplates (Nunc) were coated overnight at 4°C with
10 μg of parasite antigen/ml in bicarbonate coating buffer (pH 9.6). Wells
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